Hemophilia B Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure

Hemophilia B Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure
The Hemophilia B market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hemophilia B pipeline products will significantly revolutionize the Hemophilia B market dynamics.

DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The Hemophilia B market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 


To Know in detail about the Hemophilia B market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hemophilia B Market Insights


Some of the key facts of the Hemophilia B Market Report: 

  • The Hemophilia B market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In December 2023, Centessa Pharmaceuticals unveiled fresh insights from a Phase IIa investigation into SerpinPC’s potential for addressing hemophilia. Segment 5 findings from the Phase IIa study (AP-0101) underscored the sustained positive safety and tolerance record of SerpinPC, alongside enduring efficacy outcomes, highlighted by a remarkable 96% decline in the median all-bleed annualized bleeding rate (ABR) compared to the prospective baseline.
  • In June 2023, CSL Behring, a prominent figure in the global biotechnology sphere, disclosed that the initial recipient in the United States has been administered with HEMGENIX® (etranacogene dezaparvovec-drlb), an FDA-approved treatment for hemophilia B. HEMGENIX stands as the premier gene therapy tailored for adults grappling with hemophilia B who are either undergoing factor IX prophylaxis therapy, experiencing life-threatening bleeding episodes, or encountering recurrent, severe spontaneous bleeding episodes.
  • Sanofi is looking ahead to the projected schedule for submitting fitusiran in 2024 for hemophilia A and B, followed by a timeline extending to 2025 and beyond for hemophilia A and B in pediatric patients.
  • The overall number of diagnosed prevalent cases of Hemophilia B across the 7MM was estimated to be approximately 11,000 in 2023 and is anticipated to rise throughout the duration of the study.
  • In the EU4 and the UK, France had the highest number of diagnosed prevalent cases of Hemophilia B, totaling around 1,680 cases, followed by the UK and Italy. Conversely, Spain had the fewest diagnosed prevalent cases of Hemophilia B in 2023.
  • Among patients with Hemophilia B, those without inhibitors constitute a larger proportion of cases. In the US, approximately 200 cases were attributed to inhibitors, while around 4,000 cases were classified as non-inhibitor cases in 2023.
  • Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, and others
  • Key Hemophilia B Therapies: Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, Serpin, and others
  • The lowest prevalent population of Hemophilia B was recorded in Spain


Hemophilia B Overview

Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. The severity of hemophilia that a person has is determined by the amount of factor IX (FIX) in the blood.


Get a Free sample for the Hemophilia B Market Report:



Hemophilia B Market  

The dynamics of the Hemophilia B market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 


Hemophilia B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.


Hemophilia B Epidemiology Segmentation:

The Hemophilia B market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Hemophilia B
  • Prevalent Cases of Hemophilia B by severity
  • Gender-specific Prevalence of Hemophilia B
  • Diagnosed Cases of Episodic and Chronic Hemophilia B


Download the report to understand which factors are driving Hemophilia B epidemiology trends @ Hemophilia B Epidemiological Insights


Hemophilia B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched during the study period. The analysis covers Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug. 


Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hemophilia B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.


Hemophilia B Therapies and Key Companies

  • Marstacimab (PF-06741086): Pfizer
  • SPK-9001: Pfizer/Spark Therapeutics
  • Fitusiran: Sanofi/ Alnylam Pharmaceuticals
  • AMT-061: CSL Behring/ uniQure
  • Concizumab: Novo Nordisk
  • FLT180a: Freeline Therapeutics
  • SerpinPC: ApcinteX


To know more about Hemophilia B treatment, visit @ Hemophilia B Medications


Hemophilia B Market Drivers

  • Popularity of Gene Therapy
  • Increased Focus on Prophylactic Treatment
  • Development of Novel Treatments with extended half-life


Hemophilia B Market Barriers

  • High Cost of Treatment
  • Inconvenience and Scheduling Barriers
  • Lack of Skilled Healthcare Professionals


Hemophilia B Market Strengths

  • Hemophilia B falls under rare conditions and along with premium pricing the company can also get the orphan designations and can get additional benefits like 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees, and other benefits. 
  • Advances in technology, such as gene editing and personalized medicine, hold promising prospects for the hemophilia B market.


Hemophilia B Market Opportunities

  • Very limited treatment options are available for the severe segment (~35% of total hemophilia B) and there is huge unmet need in this setting. 
  • There is a need for comprehensive supportive care and management strategies that includes education, counseling, physical therapy, and psychological support for patients and their families to effectively manage the impact of hemophilia B on their daily lives.


Scope of the Hemophilia B Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Hemophilia B Companies: Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, CSL Behring, uniQure, Novo Nordisk, Freeline Therapeutics, ApcinteX, and others
  • Key Hemophilia B Therapies: Marstacimab (PF-06741086), SPK-9001, Fitusiran, AMT-061, Concizumab, FLT180a, Serpin, and others
  • Hemophilia B Therapeutic Assessment: Hemophilia B current marketed and Hemophilia B emerging therapies
  • Hemophilia B Market Dynamics: Hemophilia B market drivers and Hemophilia B market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Hemophilia B Unmet Needs, KOL’s views, Analyst’s views, Hemophilia B Market Access and Reimbursement 


Discover more about therapies set to grab major Hemophilia B market share @ Hemophilia B market forecast


Table of Contents 

1. Hemophilia B Market Report Introduction

2. Executive Summary for Hemophilia B

3. SWOT analysis of Hemophilia B

4. Hemophilia B Patient Share (%) Overview at a Glance

5. Hemophilia B Market Overview at a Glance

6. Hemophilia B Disease Background and Overview

7. Hemophilia B Epidemiology and Patient Population

8. Country-Specific Patient Population of Hemophilia B 

9. Hemophilia B Current Treatment and Medical Practices

10. Hemophilia B Unmet Needs

11. Hemophilia B Emerging Therapies

12. Hemophilia B Market Outlook

13. Country-Wise Hemophilia B Market Analysis (2020–2034)

14. Hemophilia B Market Access and Reimbursement of Therapies

15. Hemophilia B Market Drivers

16. Hemophilia B Market Barriers

17.  Hemophilia B Appendix

18. Hemophilia B Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight


About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/